NLY01 (2.5 mg) for Parkinson's Disease

"This clinical trial requires participants to be between 30 and 80 years old. On the other hand, 27 studies are open for individuals younger than 18 while 481 studies focus on those over 65."

"Patients have access to a broad range of medical facilities for this clinical trial, such as Booth Gardner Parkinson's Care Center in Kirkland, University of Michigan Hospital in Ann Arbor, and Massachusetts General Hospital Clinical Trials Pharmacy in Boston. Altogether there are 61 sites available nationwide."

"With NLY01's 2.5 mg dosage being subject to a Phase 2 trial, our team at Power estimates its safety on a scale of 1-3 as a score of 2 due to the absence of efficacy data but the presence of safety records."

"The ongoing research is recruiting 255 adults between the ages of 30-80 who are diagnosed with Parkinson's disease using UK Brain Bank Clinical Diagnostic criteria or Movement Disorder Society Research Criteria, as well as assessments and DaTscan test results consistent with a diagnosis."

"According to the available data hosted on clinicaltrials.gov, this specific medical study has ceased accepting participants at present; however, there are 484 other trials actively recruiting patients as of now. This trial was initially posted in February 2020 and last updated in November 2022."